European Journal of Surgical Oncology
Volume 32, Issue 7 , Pages 698-706 , September 2006

Concepts in gynaecological pathology: Recent advances and their clinical relevance

,Accepted 10 April 2006.

References 

  1. Taylor HC. Malignant and semi-malignant tumours of the ovary. Surg Gynecol Obstet. 1929;48:204–230
  2. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumours. Am J Surg Pathol. 1996;20:1331–1345
  3. Eichhorn JH, Bell DA, Young RH, Scully RE. Ovarian serous borderline tumours with micropapillary and cribriform patterns: A study of 40 Cases and comparison with 44 cases without these patterns. Am J Surg Pathol. 1999;23:397–409
  4. Seidman JD, Kurman RJ. Subclassification of serous borderline tumours of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced-stage cases. Am J Surg Pathol. 1996;20:1331–1345
  5. Prat J, De Nictolis M. Serous borderline tumours of the ovary: a long term follow up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol. 2002;26:1111–1128
  6. Gilks CB, Alkushi A, Yue JJ, Lanvin D, Ehlen TG, Miller DM. Advanced-stage serous borderline tumours of the ovary: A clinicopathological study of 49 cases. Int J Gynaecol Pathol. 2003;22:29–36
  7. Slomovitz BM, Caputo TA, Gretz HF, Economos K, Tortoriello DV, Schlosshaucr PW, et al. A comparative analysis of 57 serous borderline tumours with and without a non-invasive micropapillary component. Am J Surg Pathol. 2002;26:592–600
  8. McCaughey WTE, Kirk ME, Lester W, Dardick I. Peritoneal epithelial lesions associated with proliferative serous tumours of the ovary. Histopathology. 1984;8:195–208
  9. Seidman JD, Kurman RJ. Ovarian serous borderline tumours: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000;31:539–557
  10. Bell KA, Smith Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypically proliferative serous tumours (borderline) and micropapillary serous carcinomas. Am J Surg Pathol. 2001;25:419–432
  11. Alvarez AA, Moore WF, Robboy SJ, Bentley RC, Gumbs C, Futreal PA, et al. K-ras mutations in Mullerian inclusion cysts associated with serous borderline tumours. Gynecol Oncol. 2001;80:201–206
  12. Diebold J, Amann G, Seemuller F, Mayr D. Diagnostic and molecular genetic pathology of serous borderline tumours of the ovary. Curr Diagn Pathol. 2004;10:318–325
  13. Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence of the multifocal origin of bilateral and advanced human serous borderline ovarian tumours. Cancer Res. 1998;58:2328–2330
  14. Tan LK, Flynn SD, Carangiu ML. Ovarian serous borderline tumours with lymph node involvement: Clinicopathologic and DNA content study of seven cases and review of literature. Am J Surg Pathol. 1994;18:904–912
  15. In:  Tavassoli FA,  Devilee P editor. WHO Classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003;
  16. Fisher ER, Krieger JS, Skirpan PJ. Ovarian cystoma. Clinicopathological observations. Cancer. 1955;8:437–445
  17. Hart WR, Norris JH. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer. 1973;31:1031–1045
  18. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. Atlas of tumor pathology, third series, fascicle 23. Washington, DC: Armed Forces Institute of Pathology; 1998;pp. 17–54
  19. Rodriguez IM, Irving JA, Prat J. Endocervical-like mucinous borderline tumors of ovary: A clinicopathologic analysis of 31 cases. Am J Surg Pathol. 2004;28:1311–1318
  20. Czernobilsky B, Morris WJ. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet Gynecol. 1979;53:318–323
  21. Chaiten BA, Gershenson DM, Evans HL. Mucinous tumors of the ovary: a clinicopathologic study of 70 cases. Cancer. 1985;55:1958–1962
  22. Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26(12):1529–1541
  23. Rutgers JL, Scully RE. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy: A clinicopathologic analysis. Cancer. 1988;61:340–348
  24. Rutgers JL, Scully RE. Ovarian mixed-epithelial papillary cystadenomas of borderline malignancy of Mullerian type: A clinicopathologic analysis. Cancer. 1988;61:546–554
  25. Hoerl HD, Hart WR. Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up. Am J Surg Pathol. 1998;22:1449–1462
  26. Koern J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982: a review of clinicopathologic features and treatment modalities. Cancer. 1993;71:1810–1820
  27. Russell P, Merkur H. Proliferating ovarian “epithelial” tumors: a clinicopathological analysis of 144 cases. Aust N Z Obstet Gynaecol. 1979;19:45–51
  28. Nomura K, Aizawa S. Noninvasive, microinvasive, and invasive mucinous carcinomas of the ovary. A clinicopathologic analysis of 40 cases. Cancer. 2000;89:154–156
  29. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with “pseudomyxoma peritonei”. Am J Surg Pathol. 2000;24:1447–1464
  30. Riopol MA, Ronnet BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors; atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive and metastatic carcinoma. Am J Surg Pathol. 1999;23:617–635
  31. Rodriguez IM, Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol. 2002;26:139–152
  32. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinoma of the ovaries: Incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985–993
  33. Lash RH, Hart WR. Intestinal adenocarcinomas metastatic to the ovaries: A clinicopathologic evaluation of 22 cases. Am J Surg Pathol. 1987;11:114–121
  34. Young R, Gilks B, Scully R. Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei: a clinicopathologic analysis of 22 cases supporting an origin in the appendix. Am J Surg Pathol. 1991;15:415–429
  35. Prayson RA, Hart WR, Petras RE. Pseudomyxoma peritonei: a clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors. Am J Surg Pathol. 1994;18:591–603
  36. Ronnett BM, Kurman RJ, Shmookler BM, Sugarbaker PH, Young RH. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. Am J Surg Pathol. 1997;21:1144–1155
  37. Young RH, Hart WR. Metastases from carcinomas of the pancreas simulating primary mucinous tumors of the ovary: a report of seven cases. Am J Surg Pathol. 1983;13:748–756
  38. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary. Gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27:281–292
  39. Lagendijk JH, Mullink H, van Diest P, Meijer GA, Meijer CJ. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin: Comparison between a statistical and an intuitive approach. J Clin Pathol. 1999;52:283–290
  40. Lagendijk JH, Mullink H, van Diest PJ, Meijer GA, Meijer CJ. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol. 1998;29:491–497
  41. Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynaecol Pathol. 2002;21:391–400
  42. Lee MJ, Lee HS, Kim WH, Choi Y, Yang M. Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol. 2003;16:403–410
  43. Park SY, Kim HS, Hong EK, Kim WH. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol. 2002;33:1078–1085
  44. Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SF. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol. 2003;31:672–677
  45. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: A immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303–310
  46. Baergen RN, Rutgers JL. Mural nodules in common epithelial tumors of the ovary. Int J Gynecol Pathol. 1994;13:62–72
  47. Parazzini F, Franceschi S, La Vecchia C, Chatenoud L, Di Cintio E. The epidemiology of female genital tract cancers. Int J Gynecol Cancer. 1997;7:169–181
  48. Bokhman JV. Two pathogenetic types of endometrial carcinomas. Gynecol Oncol. 1983;15:10–17
  49. Sherman ME, Sturgeon S, Brinton LA, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol. 1997;10:963–968
  50. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 2001;32(6):569–577
  51. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40:55–65
  52. Longacre TA, Hendrickson MR. Diffusely infiltrative endometrial adenocarcinoma. An adenoma malignum pattern of myoinvasion. Am J Surg Pathol. 1999;23:69–78
  53. Kaku T, Tsuruchi N, Tsukamoto N, Hirakawa T, Kamura T, Nakano H. Reassessment of myometrial invasion in endometrial carcinoma. Obstet Gynecol. 1994;84(6):979–982
  54. Mittal KR, Barwick KW. Diffusely infiltrating adenocarcinoma of the endometrium: a subtype with a poor prognosis. Am J Surg Pathol. 1988;12:754–758
  55. Lee KR, Vacek PM, Belinson JL. Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma. Gynecol Oncol. 1994;54:10–18
  56. Tambouret R, Bell DA, Young RH. Microcystic endocervical adenocarcinomas: a report of eight cases. Am J Surg Pathol. 2000;24(3):369–374
  57. Hendrickson MR, Ross J, Kempson RL. Toward the development of morphologic criteria for well-differentiated adenocarcinoma of the endometrium. Am J Surg Pathol. 1983;7:819–838
  58. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995;26:1268–1274
  59. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma. Diagnosis and clinicopathologic correlation. Am J Surg Pathol. 2000;24:726–732
  60. Soslow RA, Pirog E, Isaacson C. Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol. 2000;24:726–732
  61. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24 year population based study. Gynecol Oncol. 2000;78(2):97–105
  62. Shin CH, Schorge JO, Lee KR, Sheets EE. Conservative management of adenocarcinoma in situ of the cervix. Gynecol Oncol. 2000;79(1):1–5
  63. Ostor AG, Duncan A, Quinn M, Rome R. Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases. Gynecol Oncol. 2000;79(2):207–210
  64. Goldstein NS, Mani A. The status and distance of cone biopsy margins as a predictor of excision adequacy for endocervical adenocarcinoma in situ. Am J Clin Pathol. 1998;109(6):727–732
  65. Denehy TR, Gregori CA, Breen JL. Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix. Obstet Gynecol. 1997;90(1):1–6
  66. A new proposal regarding criteria for Stage Ia cancer in the uterine cervix. The Joint Study Committee on Stage Ia Cancer in their Uterine Cervix: The Study Group on Criteria of Stage Ia of the Uterine Cervix; The Cancer Committee of the Japan Society of Obstetrics and Gynecology; The Japan Joint Committee on TNM Classification of Malignant Tumors. Gynecol Oncol. 1979;8(3):353–369
  67. Burghardt E, Holzer E. Diagnosis and treatment of microinvasive carcinoma of cervix uteri. Obstet Gynecol. 1977;49(6):641–653
  68. Fu YS, Berek JS, Hilborne LH. Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix. Appl Pathol. 1987;5(1):47–56
  69. Brand M, Lickrish GM, Colgan TJ. The anatomic distribution of cervical adenocarcinoma in situ: implications for treatment. Am J Obstet Gynecol. 1987;157:21–25
  70. Anderson ES, Arffmann E. Adenocarcinoma in situ of the uterine cervix: a clinico-pathologic study of 36 cases. Gynecol Oncol. 1989;35:1–7
  71. Östör AG. Early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol. 2000;19:29–38
  72. Sivanesaratnam V, Sen DK, Jayalakshmi P, Ong G. Radical hysterectomy and pelvic lymphadenectomy for early invasive cancer of the cervix—14-year experience. Int J Gynaecol Cancer. 1993;3:231–238
  73. Yaegashi N, Sato S, Inoue Y. Conservative surgical treatment in cervical cancer with 3 to 5 mm stromal invasion in the absence of confluent invasion and lymph-vascular space involvement. Gynecol Oncol. 1994;54(3):333–337
  74. Jones MW, Silverberg SG, Kurman RJ. Well-differentiated villoglandular adenocarcinoma of the uterine cervix: a clinicopathological study of 24 cases. Int J Gynecol Pathol. 1993;12(1):1–7
  75. Gilks CB, Young RH, Aguirre P, DeLellis RA, Scully RE. Adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. A clinicopathological and immunohistochemical analysis of 26 cases. Am J Surg Pathol. 1989;13(9):717–729
  76. McGowan L, Young RH, Scully RE. Peutz-Jeghers syndrome with “adenoma malignum” of the cervix. A report of two cases. Gynecol Oncol. 1980;10(2):125–133
  77. Reich O, Tamussino K, Lahousen M, Pickel H, Haas J, Winter R. Clear cell carcinoma of the uterine cervix: pathology and prognosis in surgically treated stage IB-IIB disease in women not exposed in utero to diethylstilbestrol. Gynecol Oncol. 2000;76(3):331–335
  78. Hatch EE, Palmer JR, Titus-Ernstoff L, Noller KL, Kaufman RH. Papillary serous adenocarcinoma of the uterine cervix: a report of three cases. Mod Pathol. 1992;5(4):426–431
  79. Brainard JA, Hart WR. Adenoid basal epitheliomas of the uterine cervix: a reevaluation of distinctive cervical basaloid lesions currently classified as adenoid basal carcinoma and adenoid basal hyperplasia. Am J Surg Pathol. 1998;22(8):965–975
  80. Kurman RJ, Toki T, Schiffman MH. Basaloid and warty carcinomas of the vulva: distinctive types of squamous cell carcinoma frequently associated with human papillomaviruses. Am J Surg Pathol. 1993;17:133–145
  81. Hording U, Junge J, Daugaard S, Lundvall F, Poulsen H, Bock JE. Vulvar carcinoma and papillomaviruses: indications for two different etiologies. Gynecol Oncol. 1994;52:241–246
  82. Trimble CL, Hildesheim A, Brinton LA, Shah KV, Kurman RJ. Heterogeneous etiology of squamous carcinoma of the vulva. Obstet Gynecol. 1996;87(1):59–64
  83. Nascimento AF, Granter SR, Cviko A, Yuan L, Hecht JL, Crum CP. Vulvar acanthosis with altered differentiation: a precursor to verrucous carcinoma?. Am J Surg Pathol. 2004;28(5):638–643
  84. Fox H, Wells M. Recent advances in the pathology of the vulva. Histopathology. 2003;42:209–216
  85. Hart WR. Vulvar intraepithelial neoplasia: historical aspects and current status. Int J Gynecol Pathol. 2001;20:16–30
  86. Yang B, Hart WR. Vulvar intraepithelial neoplasia of the simplex (differentiated type): a clinicopathological study including analysis of HPV and p53 expression. Am J Surg Pathol. 2000;24:429–441
  87. Fiorica JV, Cavanagh D, Marsden DE, Shepherd JH, Ruffolo EH, Songster CL. Carcinoma in situ of the vulva: 24 years experience in southwest Florida. South Med J. 1988;81:323–327
  88. Chafe W, Richards A, Morgan I, Wilkinson EJ. Unrecognised invasive carcinomas in vulvar intraepithelial neoplasia (VIN). Gynecol Oncol. 1988;31:154–165
  89. Thuis YN, Campion M, Fox H, Hacker NF. Contemporary experience of the management of vulvar intraepithelial neoplasia. Int J Gynecol Cancer. 2000;10:223–227

PII: S0748-7983(06)00172-7

doi: 10.1016/j.ejso.2006.04.007

European Journal of Surgical Oncology
Volume 32, Issue 7 , Pages 698-706 , September 2006

Article Tools

* Image Usage & Resolution